Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 11/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329106 | 0.91 | PTGS2 (0.37) | MAPK14PTGS2POLBRAB9ASMN1; SMN2 | |
| SCHEMBL3327277 | 0.78 | ALDH1A1 (0.33) | TP53NFKB1NFKB2RELASMN1; SMN2 | |
| SCHEMBL3328548 | 0.77 | AGTR1 (0.32) | POLBSMN1; SMN2 | |
| SCHEMBL9031516 | 0.77 | PTGS1 (0.43) | PTGS1PTGS2POLBSMN1; SMN2 | |
| SCHEMBL9033026 | 0.76 | AGTR1 (0.38) | PTGS1PTGS2POLBSMN1; SMN2 | |
| SCHEMBL9034442 | 0.75 | NPC1 (0.36) | NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL22846841 | 0.75 | CYP3A4 (0.35) | POLBSMN1; SMN2 | |
| SCHEMBL3326379 | 0.73 | AGTR1 (0.35) | POLBRAB9ASMN1; SMN2 | |
| SCHEMBL18940668 | 0.73 | AGTR1 (0.42) | NPC1TP53POLBPKMNFKB1 | |
| SCHEMBL30743612 | 0.72 | ABCG2 (0.55) | NPC1POLBPKMRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | DENOVAMED INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2008128321-A1 | THERAPEUTIC PRO-ANTIBIOTIC AGENTS AND METHODS OF USE THEREOF | DENOVAMED INC. (CA) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | NAT1, NAPEPLD, NR1I2 | MAPK14 4071/4885PTGS1 810/4885PTGS2 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.